SCHEMBL2215928

SCHEMBL2215928

C=CCc1[c]c(=O)oc2ccccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.43
CA1 P00915 3/20 0.43
CA9 Q16790 3/20 0.43
CYP3A4 P08684 3/20 0.41
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 3/20 0.41
GLA P06280 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
PGAM1 P18669 1/20 0.41
MAOA P21397 1/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CYP2A6 P11509 1/20 0.37
VKORC1 Q9BQB6 1/20 0.37
NQO1 P15559 2/20 0.36
GAA P10253 1/20 0.36
MEN1 O00255 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5140132 0.72 KDM4E (0.40) CA12CA1CA9CYP3A4ALDH1A1
SCHEMBL5134333 0.72 CA12 (0.34) CA12CA1CA9CYP3A4MAPT
SCHEMBL3799324 0.70 CA12 (0.57) CA12CA1CA9CYP3A4ALDH1A1
SCHEMBL3164161 0.69 CA12 (0.48) CA12CA1CA9CYP3A4ALDH1A1
SCHEMBL2192615 0.69 KDM4E (0.48) CA12CA1CA9CYP3A4ALDH1A1
SCHEMBL4499932 0.69 KDM4E (0.50) CA12CA1CA9CYP3A4ALDH1A1
SCHEMBL6448403 0.69 NPC1 (0.45) CA12CA1CA9CYP3A4ALDH1A1
SCHEMBL7143392 0.68 VKORC1 (0.71) CYP3A4ALDH1A1KDM4EVKORC1NQO1
SCHEMBL3988877 0.68 GAA (0.57) CYP3A4ALDH1A1KDM4EMAPTHPGD
SCHEMBL5478821 0.68 VKORC1 (0.51) CA12CA1CA9CYP3A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994323-B2 Chromen-2-one derivatives NEUROSEARCH A/S (DK) 2011-08-09 US disclosed
EP-2158200-B1 NOVEL CHROMEN-2-ONE DERIVATIVES NEUROSEARCH AS (DK) 2011-07-13 EP disclosed
US-20100217002-A1 NOVEL CHROMEN-2-ONE DERIVATIVES NEUROSEARCH A/S (DK) 2010-08-26 US disclosed
EP-2158200-A1 NOVEL CHROMEN-2-ONE DERIVATIVES NeuroSearch A/S (DK) 2010-03-03 EP disclosed
WO-2008138854-A1 NOVEL CHROMEN-2-ONE DERIVATIVES NEUROSEARCH A/S (DK) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100217002-A1 NOVEL CHROMEN-2-ONE DERIVATIVES CBX2, CYP2J2, CDYL2 CA12 1775/4885CA1 4334/4885CA9 4022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.